Clinical Trial Update: Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) [Phase 3]

View source ↗

Summary

Phase 3 trial update for GTX-102 in pediatric Angelman syndrome; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• GTX-102

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Angelman Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING